Aurora Cannabis Completes Larssen and H2 Biopharma Acquisitions

Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that, further to its press releases of November 23, 2017, the Company has completed the acquisitions of Larssen Ltd, a globally leading greenhouse engineering and design consultancy, and that of H2 Biopharma, a late-stage ACMPR applicant based in Quebec.-

Aurora Cannabis Increases Ownership Interest in Radient Technologies

Aurora Cannabis Inc. ("Aurora") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Radient Technologies Inc. ("Radient) (TSX-V: RTI) today announced that further to the investor rights agreement between both companies, as announced on November 6, 2017, Aurora will make a further investment in Radient for a total of $12 million

Aurora Cannabis Still Committed to Cannimed Takeover Bid

Following the November 28, 2017 CanniMed Therapeutics Inc. (TSX: CMED) announcement that it has unilaterally adopted a shareholders' rights plan in response to the compelling offer made by Aurora Cannabis Inc. (TSX: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) to CanniMed's shareholders, Aurora provides the following initial response.

Maricann Group Inc. Signs Letter of Intent with ABLE BC

Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF)(FRANKFURT:75M) announces it has entered into a non-binding letter of intent with the Alliance of Beverage Licensees, the advocacy organization representing British Columbia's private liquor industry which outlines a proposed relationship between ABLE BC and Maricann for, among other things, the supply of Maricann product to ABLE BC members.